Two Proof Points In One Session
Wednesday supplied two different demonstrations of what can happen when the market starts paying for validated biology again.
Moderna (MRNA 0.00%↑) surged 177% after the company and Merck announced that their personalized mRNA cancer therapy, combined with Keytruda, met both key endpoints in a Phase 3 melanoma trial. It was the first positive Phase 3 readout for an individualized neoantigen therapy and an mRNA-based cancer treatment.
Twist Bioscience (TWST 0.00%↑) rose 23% during the same session after Anthropic disclosed that Claude had designed protein binders against 14 of 15 testable targets. Twist and Adaptyv Bio independently built and tested the designs in the lab, confirming 354 binders from 1,320 designs.
The catalysts were different, but the investment message was related. Capital is rewarding clinical validation at one end of the biotech stack and tools that may compress early discovery timelines at the other.
Positioned, But Early
We currently have an open TWST trade. We also closed our MRNA trade last month for a 491% return on net debit. That July expiration was too short to capture Wednesday’s move, which is a clean reminder that tenor determines which catalysts an options trade can reach.
Two of today’s trades come from our Multibaggers list, a subset of our Market Watchers X list made up of analysts with multiple 100%+ winners. Those analysts supply potential asymmetric ideas; our technical screens, catalyst work, option structures and price discipline determine when and how we act.
One biotech has positive late-stage data and several additional program readouts ahead. The other has a marketed screening product and a near-term regulatory binary. Both passed our Trend & Consolidation screen, which looks for strong technical ratings paired with constructive setups.
Today’s third trade comes from Portfolio Armor’s Top Names, the securities our quantitative system estimates will have the highest returns over the next six months. It’s a defensive managed-care name that was the only member of Wednesday night’s Top Ten to clear our strict technical screen.
The structures reflect the different roadmaps. The Top Names trade and the longer-dated biotech trade both enter for credits. The regulatory binary uses a debit structure, but only at a price below all three of our fair-value estimates. All three are defined-risk four-leg combos. Paid subscribers will find the names, complete structures, entry limits and exit plans below.
Today’s Top Names Trade
Medicare Advantage recovery / membership growth and margin-normalization theme.
RSI: 49; Chartmill Technical Rating: 7; Setup Rating: 7; Fundamental Rating: 4.
